BMP-7 Antibody [Unconjugated]

• Reactivity: Hu, Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

BMP-7 Antibody [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human BMP‑7
  Ser293-His431
  Accession # P18075
• Specificity: Detects human and mouse BMP-7 in Western blots. In this format, less than 1% cross-reactivity with recombinant human (rh) BMP-2, rhBMP‑3, rhBMP‑4, rhBMP‑5, and rhBMP‑6 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: BMP7
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BMP-7 Antibody [Unconjugated]

• BMP7
• BMP-7
• bone morphogenetic protein 7
• Eptotermin alfa
• OP-1
• OP-1OP1
• Osteogenic protein 1

Background

Bone morphogenetic protein 7 (BMP-7), also known as osteogenic protein 1 (OP-1), is a widely expressed TGF-beta superfamily member with important functions during embryogenesis, in the adult, and in disease (1, 2). Human BMP-7 is synthesized with a 29 amino acid (aa) signal sequence, a 263 aa propeptide, and a 139 aa growth factor domain (3, 4). The growth factor domain of human BMP-7 shares 98% aa sequence identity with mouse and rat BMP-7. The BMP-7 propeptide is cleaved intracellularly but often remains associated with the mature C-terminus. Based on in vivo and in vitro studies, BMP-7 has the potential to be secreted as a disulfide-linked mature homodimer, or particularly as a heteromeric complex that consists of two propeptides noncovalently associated with a mature disulfide-linked homodimer (5, 6). The presence of the propeptides in BMP-7 appears to stabilize the molecule and provide a docking mechanism for extracellular storage on molecules such as fibrillin-1 and -2 (5, 6). The propeptides themselves do not impart latency to the complex. BMP-7 binding to type II receptors rapidly displaces the prodomain:mature molecule interaction and has no effect on activity. But it is suggested that immobilized BMP-7 (via prodomain:fibrillin) is inactive, allowing for possible long-term storage of the molecule (6). BMP-7 interacts with the type 2 receptors Activin RIIA, Activin RIIB, and BMPR-II and the type 1 receptors Activin RIA, BMPR-IA, and BMPR-IB (2, 6). BMP-7 may also be processed into a disulfide-linked heterodimer with either BMP-2 or BMP-4. Such complexes may show increased potency and range of activity compared to BMP-7 homodimers (7 - 9). BMP-7 plays a role in a variety of organ systems. It promotes new bone formation and nephron development (10, 11), inhibits the branching of prostate epithelium (12), and antagonizes epithelial-mesenchymal transition (EMT) (13 - 15). In pathological conditions, BMP-7 inhibits tumor growth and metastasis (14), ameliorates fibrotic damage in nephritis (13), and promotes neuroregeneration following brain ischemia (16).

1. Chen, D. et al. (2004) Growth Factors 22:233.
2. Kishigami, S. and Y. Mishina (2005) Cytokine Growth Factor Rev. 16:265.
3. Ozkaynak, E. et al. (1990) EMBO J. 9:2085.
4. Celeste, A.J. et al. (1990) Proc. Natl. Acad. Sci. 87:9843.
5. Gregory, K.E. et al. (2005) J. Biol. Chem. 280:27970.
6. Sengle, G. et al. (2008) J. Mol. Biol. 381:1025.
7. Israel, D.I. et al. (1996) Growth Factors 13:291.
8. Aono, A. et al. (1995) Biochem. Biophys. Res. Commun. 210:670.
9. Nishimatsu, S. and G.H. Thomsen (1998) Mech. Dev. 74:75.
10. Sampath, T.K. et al. (1992) J. Biol. Chem. 267:20352.
11. Kazama, I. et al. (2008) J. Am. Soc. Nephrol. 19:2181.
12. Grishina, I.B. et al. (2005) Dev. Biol. 288:334.
13. Zeisberg, M. et al. (2003) Nat. Med. 9:964.
14. Buijs, J.T. et al. (2007) Am. J. Pathol. 171:1047.
15. Yu, M.-A. et al. (2009) J. Am. Soc. Nephrol. 20:567.
16. Chou, J. et al. (2006) J. Neurol. Sci. 240:21.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for BMP-7 Antibody (AF354)(1)

Publication using AF354

• Knosp WM, Scott V, Bachinger HP, Stadler HS HOXA13 regulates the expression of bone morphogenetic proteins 2 and 7 to control distal limb morphogenesis. Development, 2004-09-01;131(18):4581-92. 2004-09-01 [PMID: 15342482] (IHC, Mouse)

Bioinformatics

• Gene Symbol: BMP7
• Uniprot:
  • P18075()